TITLE

AMINOHYDROLASES ACTING ON ADENINE, ADENOSINE AND THEIR DERIVATIVES

AUTHOR(S)
Pospisilova, Hana; Frebort, Ivo
PUB. DATE
June 2007
SOURCE
Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Adenine and adenosine-acting aminohydrolases are important groups of enzymes responsible for the metabolic salvage of purine compounds. Several subclasses of these enzymes have been described and given current knowledge of the full genome sequences of many organisms, it is possible to identify genes encoding these enzymes and group them according to their primary structure. Methods and Results: This article is a short overview of the enzymes classified as adenine and adenosine deaminase. It summarises knowledge of their occurrence, genetic basis and their catalytic and structural properties. Conclusions: These enzymes are constitutive components of purine metabolism and their impairment may cause serious medical disorders. In humans, adenosine deaminase deficiency is linked to severe combined immunodeficiency and as such the enzyme has been approved for the first gene therapy trial. The role of these enzymes in plants is unclear, since the activity was has not been detected in extracts and putative genes have not been yet cloned and analyzed. A literature search and amino acid identity comparison show that Ascomycetes contain only adenine deaminase, but not adenosine deaminase, despite the fact that corresponding genes are annotated in databases as the adenosine cleaving enzymes because they share the same conserved domain.
ACCESSION #
31371720

 

Related Articles

  • Progress in Genetic Therapy for Severe Combined Immunodeficiency Associated With Adenosine Deaminase Deficiency. Williams, David A. // Molecular Therapy;Apr2009, Vol. 17 Issue 4, p577 

    The article offers a long-term follow-up of 10 patients treated with stem cell gene therapy for severe combined immunodeficiency (SCID) caused by adenosine deaminase (ADA) deficiency. According to the article, the results depict essential success in reversal of the life-threatening...

  • How I treat severe combined immunodeficiency. Gaspar, H. Bobby; Qasim, Waseem; Davies, E. Graham; Rao, Kanchan; Amrolia, Persis J.; Veys, Paul // Autocar;12/ 5/2013, Vol. 122 Issue 24, p3749 

    Severe combined immunodeficiency (SCID) arises from different genetic defects associated with lymphocyte development and function and presents with severe infections. Allogeneic hematopoietic stem cell transplantation is an extremely effective way of restoring immunity in these individuals....

  • Nowhere to hide for faulty genes.  // New Scientist;11/2/2013, Vol. 220 Issue 2941, p8 

    The article discusses the reemergence of gene therapy as a treatment for immune disorders, such adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID). Topics include the story of a 5-week-old baby, named Nina, who was diagnosed with SCID, the effectiveness of gene therapy...

  • Preclinical Demonstration of Lentiviral Vector-mediated Correction of Immunological and Metabolic Abnormalities in Models of Adenosine Deaminase Deficiency. Carbonaro, Denise A; Zhang, Lin; Jin, Xiangyang; Montiel-Equihua, Claudia; Geiger, Sabine; Carmo, Marlene; Cooper, Aaron; Fairbanks, Lynette; Kaufman, Michael L; Sebire, Neil J; Hollis, Roger P; Blundell, Michael P; Senadheera, Shantha; Fu, Pei-Yu; Sahaghian, Arineh; Chan, Rebecca Y; Wang, Xiaoyan; Cornetta, Kenneth; Thrasher, Adrian J; Kohn, Donald B // Molecular Therapy;Mar2014, Vol. 22 Issue 3, p607 

    Gene transfer into autologous hematopoietic stem cells by γ-retroviral vectors (gRV) is an effective treatment for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). However, current gRV have significant potential for insertional mutagenesis as reported in clinical...

  • 333. Preferential Targeting of Transcriptional Start Sites after Retroviral-Mediated T-Cell Gene Therapy for Adenosine Deaminase Deficiency Moratto, Daniele; Jagadeesh, Jayashree G.; Konno, Akihiro; Bosticardo, Marita; Crawford, Gregory E.; Holt, Ingeborg; Muul, Linda M.; Shurman, Shepherd H.; Wolfsberg, Tyra; Candotti, Fabio // Molecular Therapy;Jun2005, Vol. 11, p129 

    An abstract of the article "Preferential Targeting of Transcriptional Start Sites after Retroviral-Mediated T-Cell Gene Therapy for Adenosine Deaminase Deficiency," by Daniele Moratto, Jayashree G. Jagadeesh, Akihiro Konno, Marita Bosticardo, Gregory E. Crawford and Ingeborg Holt is presented.

  • Splice of life. Culver, Kenneth W. // Sciences;Jan/Feb93, Vol. 33 Issue 1, p18 

    Presents the experiments conducted to find cure for adenosine deaminase (ADA) deficiency. Use of gene therapy; Experimental stages of bone marrow transplant; Nature of immune deficiencies; Finding that ADA coated with polyethylene glycol (PEG) could survive; Advantages and disadvantages of...

  • 331. Lentivirus-Mediated Ex Vivo Gene Therapy in ADA-Deficient SCID Mice Mortellaro, Alessandra; Hernández, Raisa Jofra; Guerrini, Matteo; Tabucchi, Antonella; Carlucci, Filippo; Follenzi, Antonia; Naldini, Luigi; Bordignon, Claudio; Roncarolo, Maria Grazia; Aiuti, Alessandro // Molecular Therapy;Jun2005, Vol. 11, p128 

    An abstract of the article "Lentivirus-Mediated Ex Vivo Gene Therapy in ADA-Deficient SCID Mice," by Alessandra Mortellaro, Matteo Guerrini, Antonella Tabucchi, Filippo Carlucci, Antonia Follenzi, Luigi Naldini, Claudio Bordignon, Maria Grazia Roncarolo and Alessandro Aiuti is presented.

  • In utero gene therapy: The case for. Schneider, Holm; Coutelle, Charles // Nature Medicine;Mar1999, Vol. 5 Issue 3, p256 

    Comments on the potential risks and benefits of human in utero gene therapy for homozygous alpha-thalassemia and adenosine deaminase deficiency. Other candidate diseases for prenatal gene therapy; Effects to the pregnant woman and the unborn patient.

  • Dutch scientists plan new approach to gene therapy. van Kastern, Joost // New Scientist;8/31/90, Vol. 131 Issue 1784, p20 

    Explores the effort of scientists at the Netherlands-based University Hospital of Leiden and research organization, TNO, to develop an approach to gene therapy for severe combined immune deficiency which is caused by the lack of an enzyme called adenosine deaminase.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics